Farnesyl Protein Transferase Inhibitor

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Blast CrisisCarcinoma, Squamous CellHead and Neck NeoplasmsLeukemiaLeukemia, LymphocyticLeukemia, Myeloid, ChronicMyelodysplastic SyndromesNeoplasms

Phase 1

Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)

CompletedNCT00034684

Merck Sharp & Dohme LLCBlast Crisis, Leukemia, Leukemia, Lymphocytic +2

Start: 2001-07-31End: 2003-10-31Updated: 2015-06-17

Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)

CompletedNCT00040547

Merck Sharp & Dohme LLCNeoplasms

Start: 2001-06-30End: 2004-02-29Updated: 2015-02-18

Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)

TerminatedNCT00040534

Merck Sharp & Dohme LLCNeoplasms

Start: 2001-01-31End: 2004-07-31Updated: 2015-02-16

Phase 2

Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)

TerminatedNCT00073450

Merck Sharp & Dohme LLCCarcinoma, Squamous Cell, Head and Neck Neoplasms

Start: 2003-09-30End: 2004-06-30Updated: 2015-04-21